[{"id":"5de3ae22-f200-40ed-bea2-6427c55b3ad9","acronym":"","url":"https://clinicaltrials.gov/study/NCT06984328","created_at":"2025-06-07T14:42:38.975Z","updated_at":"2025-06-07T14:42:38.975Z","phase":"Phase 2","brief_title":"Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)","source_id_and_acronym":"NCT06984328","lead_sponsor":"Genmab","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • acasunlimab (GEN1046)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 06/30/2025","start_date":" 06/30/2025","primary_txt":" Primary completion: 07/15/2027","primary_completion_date":" 07/15/2027","study_txt":" Completion: 07/15/2029","study_completion_date":" 07/15/2029","last_update_posted":"2025-06-03"},{"id":"0275af4d-adea-470c-80d3-2b61aa1c8803","acronym":"","url":"https://clinicaltrials.gov/study/NCT01950390","created_at":"2021-01-18T08:50:38.167Z","updated_at":"2025-02-25T12:26:04.772Z","phase":"Phase 2","brief_title":"Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery","source_id_and_acronym":"NCT01950390","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF wild-type","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Yervoy (ipilimumab) • Aybintio (bevacizumab biosimilar) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Jobevne (bevacizumab-nwgd) • CS1002 (ipilimumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 169","initiation":"Initiation: 01/24/2014","start_date":" 01/24/2014","primary_txt":" Primary completion: 10/06/2021","primary_completion_date":" 10/06/2021","study_txt":" Completion: 01/31/2026","study_completion_date":" 01/31/2026","last_update_posted":"2025-02-24"},{"id":"23898e8b-63ed-4913-ab7c-2d5d7699806b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02339571","created_at":"2021-01-18T11:07:01.092Z","updated_at":"2025-02-25T12:26:15.021Z","phase":"Phase 2/3","brief_title":"A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma","source_id_and_acronym":"NCT02339571","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF wild-type","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • Leukine (sargramostim)"],"overall_status":"Recruiting","enrollment":" Enrollment 600","initiation":"Initiation: 11/23/2015","start_date":" 11/23/2015","primary_txt":" Primary completion: 06/30/2033","primary_completion_date":" 06/30/2033","study_txt":" Completion: 06/30/2033","study_completion_date":" 06/30/2033","last_update_posted":"2025-02-24"},{"id":"3b32d8a5-c5ea-4195-a505-ea0c6246c9c2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04119024","created_at":"2021-01-18T20:07:53.813Z","updated_at":"2025-02-25T12:27:21.879Z","phase":"Phase 1","brief_title":"Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors","source_id_and_acronym":"NCT04119024","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Imunace (teceleukin) • MB-101 • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 11/27/2019","start_date":" 11/27/2019","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2025-02-24"},{"id":"70fc40e8-2780-469a-93b2-3e3f813f0994","acronym":"BaseTIL-03M","url":"https://clinicaltrials.gov/study/NCT05869539","created_at":"2023-05-22T16:05:47.092Z","updated_at":"2025-02-25T13:55:13.470Z","phase":"Phase 1","brief_title":"ACT-TIL and ANV419 for Advanced Melanoma.","source_id_and_acronym":"NCT05869539 - BaseTIL-03M","lead_sponsor":"University Hospital, Basel, Switzerland","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ANV419"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 06/21/2023","start_date":" 06/21/2023","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2025-02-20"},{"id":"39739443-27b5-47de-9366-d6dcb750b600","acronym":"SGNBB228-001","url":"https://clinicaltrials.gov/study/NCT05571839","created_at":"2022-10-07T13:59:56.834Z","updated_at":"2025-02-25T14:09:10.779Z","phase":"Phase 1","brief_title":"A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors","source_id_and_acronym":"NCT05571839 - SGNBB228-001","lead_sponsor":"Seagen, a wholly owned subsidiary of Pfizer","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PF-08046049"],"overall_status":"Recruiting","enrollment":" Enrollment 275","initiation":"Initiation: 01/03/2023","start_date":" 01/03/2023","primary_txt":" Primary completion: 04/19/2027","primary_completion_date":" 04/19/2027","study_txt":" Completion: 04/18/2028","study_completion_date":" 04/18/2028","last_update_posted":"2025-02-19"},{"id":"c30bda4b-7e9e-488f-9635-25027af3f695","acronym":"","url":"https://clinicaltrials.gov/study/NCT05303493","created_at":"2022-03-31T18:53:02.337Z","updated_at":"2025-02-25T14:41:16.078Z","phase":"Phase 1","brief_title":"Camu-Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-small Cell Lung Cancer and Melanoma","source_id_and_acronym":"NCT05303493","lead_sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","biomarkers":" PD-L1 • BRAF","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 06/29/2022","start_date":" 06/29/2022","primary_txt":" Primary completion: 04/15/2025","primary_completion_date":" 04/15/2025","study_txt":" Completion: 04/15/2027","study_completion_date":" 04/15/2027","last_update_posted":"2025-02-14"},{"id":"4b6f2c6e-35f3-4b56-9b34-2f31c986974d","acronym":"BNT111-01","url":"https://clinicaltrials.gov/study/NCT04526899","created_at":"2021-01-18T21:40:45.863Z","updated_at":"2025-02-25T15:26:32.109Z","phase":"Phase 2","brief_title":"Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD-1-refractory/Relapsed, Unresectable Stage III or IV Melanoma","source_id_and_acronym":"NCT04526899 - BNT111-01","lead_sponsor":"BioNTech SE","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc) • BNT111"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 184","initiation":"Initiation: 05/19/2021","start_date":" 05/19/2021","primary_txt":" Primary completion: 01/25/2024","primary_completion_date":" 01/25/2024","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2025-02-10"},{"id":"757c7ea9-28ea-4973-bbc9-a09748839d13","acronym":"","url":"https://clinicaltrials.gov/study/NCT05039801","created_at":"2021-09-10T16:57:15.373Z","updated_at":"2025-02-25T15:35:16.395Z","phase":"Phase 1","brief_title":"IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors","source_id_and_acronym":"NCT05039801","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1 • PIK3CA • PTEN • STK11 • ARID1A • NF1 • KEAP1 • PD-1 • NFE2L2","pipe":" | ","alterations":" PIK3CA mutation • ARID1A mutation • STK11 mutation • KEAP1 mutation • NFE2L2 mutation","tags":["PD-L1 • PIK3CA • PTEN • STK11 • ARID1A • NF1 • KEAP1 • PD-1 • NFE2L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • ARID1A mutation • STK11 mutation • KEAP1 mutation • NFE2L2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Avastin (bevacizumab) • paclitaxel • Truqap (capivasertib) • IPN60090"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 09/09/2021","start_date":" 09/09/2021","primary_txt":" Primary completion: 05/29/2026","primary_completion_date":" 05/29/2026","study_txt":" Completion: 05/29/2026","study_completion_date":" 05/29/2026","last_update_posted":"2025-02-10"},{"id":"11565097-46a7-40c4-bd2e-84aac455986c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01638533","created_at":"2021-01-18T07:02:41.766Z","updated_at":"2025-02-25T14:33:33.086Z","phase":"Phase 1","brief_title":"Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction","source_id_and_acronym":"NCT01638533","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ER • AFP","pipe":"","alterations":" ","tags":["ER • AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Istodax (romidepsin)"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 08/03/2012","start_date":" 08/03/2012","primary_txt":" Primary completion: 11/29/2018","primary_completion_date":" 11/29/2018","study_txt":" Completion: 09/01/2020","study_completion_date":" 09/01/2020","last_update_posted":"2025-02-07"},{"id":"6eaf7ebc-3a8d-431d-b6e5-611012b34a31","acronym":"KEYNOTE B81","url":"https://clinicaltrials.gov/study/NCT04609566","created_at":"2021-01-19T20:32:09.814Z","updated_at":"2025-02-25T16:10:46.045Z","phase":"Phase 2","brief_title":"Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors","source_id_and_acronym":"NCT04609566 - KEYNOTE B81","lead_sponsor":"Seagen Inc.","biomarkers":" EGFR • BRAF • ALK • ROS1","pipe":" | ","alterations":" EGFR mutation • BRAF mutation • ALK mutation","tags":["EGFR • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • BRAF mutation • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Adcetris (brentuximab vedotin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 142","initiation":"Initiation: 01/26/2021","start_date":" 01/26/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2025-02-07"},{"id":"79725e7c-a938-4a9e-b556-bf960936b158","acronym":"","url":"https://clinicaltrials.gov/study/NCT03618641","created_at":"2021-09-17T01:53:43.496Z","updated_at":"2025-02-25T16:31:32.025Z","phase":"Phase 2","brief_title":"CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease","source_id_and_acronym":"NCT03618641","lead_sponsor":"Diwakar Davar","biomarkers":" CD8 • CD4 • SOX10","pipe":"","alterations":" ","tags":["CD8 • CD4 • SOX10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • vidutolimod (CMP-001)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 08/08/2018","start_date":" 08/08/2018","primary_txt":" Primary completion: 08/20/2020","primary_completion_date":" 08/20/2020","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2025-02-07"},{"id":"8faa9c2f-7698-40c3-8644-3401597d3da2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05628883","created_at":"2022-11-29T15:57:45.457Z","updated_at":"2025-02-25T16:33:12.261Z","phase":"Phase 1","brief_title":"Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma","source_id_and_acronym":"NCT05628883","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" BRAF • IL2","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • TIDAL-01"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 11/22/2022","start_date":" 11/22/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-07"},{"id":"93546d33-d260-437a-9cd5-b7629d9d588d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04708418","created_at":"2023-04-01T19:06:08.459Z","updated_at":"2025-02-25T16:38:10.265Z","phase":"Phase 2","brief_title":"A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma","source_id_and_acronym":"NCT04708418","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • vidutolimod (CMP-001) • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 10/15/2021","start_date":" 10/15/2021","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-06"},{"id":"bdabf0d8-2cf8-415a-871a-05a580f1c107","acronym":"SWOG S1801","url":"https://clinicaltrials.gov/study/NCT03698019","created_at":"2021-01-29T07:18:05.054Z","updated_at":"2025-02-25T16:37:13.668Z","phase":"Phase 2","brief_title":"A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma","source_id_and_acronym":"NCT03698019 - SWOG S1801","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 313","initiation":"Initiation: 02/15/2019","start_date":" 02/15/2019","primary_txt":" Primary completion: 09/01/2022","primary_completion_date":" 09/01/2022","study_txt":" Completion: 10/31/2025","study_completion_date":" 10/31/2025","last_update_posted":"2025-02-06"},{"id":"c2b67cc7-ce2b-4a17-af77-efced8e1526f","acronym":"E1609","url":"https://clinicaltrials.gov/study/NCT01274338","created_at":"2023-04-12T19:03:03.311Z","updated_at":"2025-02-25T16:36:09.391Z","phase":"Phase 3","brief_title":"Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery","source_id_and_acronym":"NCT01274338 - E1609","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IFNA1","pipe":"","alterations":" ","tags":["IFNA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • Intron A (interferon α-2b)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1673","initiation":"Initiation: 05/25/2011","start_date":" 05/25/2011","primary_txt":" Primary completion: 02/15/2019","primary_completion_date":" 02/15/2019","study_txt":" Completion: 03/07/2025","study_completion_date":" 03/07/2025","last_update_posted":"2025-02-06"},{"id":"d0aa4f16-7694-44b7-8f9e-f75259b43f62","acronym":"","url":"https://clinicaltrials.gov/study/NCT05544929","created_at":"2022-09-19T14:56:40.664Z","updated_at":"2025-02-25T16:39:18.617Z","phase":"Phase 1","brief_title":"A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers","source_id_and_acronym":"NCT05544929","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Tevimbra (tislelizumab-jsgr) • KFA115"],"overall_status":"Recruiting","enrollment":" Enrollment 180","initiation":"Initiation: 10/26/2022","start_date":" 10/26/2022","primary_txt":" Primary completion: 02/20/2026","primary_completion_date":" 02/20/2026","study_txt":" Completion: 02/20/2026","study_completion_date":" 02/20/2026","last_update_posted":"2025-02-06"},{"id":"6b19c0a6-ae66-4201-9c5b-978c28f8c121","acronym":"","url":"https://clinicaltrials.gov/study/NCT04514484","created_at":"2021-01-18T21:38:07.896Z","updated_at":"2025-02-25T16:45:04.992Z","phase":"Phase 1","brief_title":"Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV","source_id_and_acronym":"NCT04514484","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD276 • VTCN1 • CD4 • HHLA2","pipe":"","alterations":" ","tags":["CD276 • VTCN1 • CD4 • HHLA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 11/22/2021","start_date":" 11/22/2021","primary_txt":" Primary completion: 11/02/2025","primary_completion_date":" 11/02/2025","study_txt":" Completion: 11/02/2025","study_completion_date":" 11/02/2025","last_update_posted":"2025-02-05"},{"id":"d9fb5689-9e2f-4e36-a900-e153d3a0a937","acronym":"","url":"https://clinicaltrials.gov/study/NCT06075524","created_at":"2023-10-10T14:12:06.920Z","updated_at":"2025-02-25T16:47:06.974Z","phase":"","brief_title":"Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types","source_id_and_acronym":"NCT06075524","lead_sponsor":"Mayo Clinic","biomarkers":" CD8 • NKG7","pipe":"","alterations":" ","tags":["CD8 • NKG7"],"overall_status":"Recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 06/15/2015","start_date":" 06/15/2015","primary_txt":" Primary completion: 08/31/2025","primary_completion_date":" 08/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-05"},{"id":"54486d49-51b2-4eb7-8a05-f17bf1217be9","acronym":"MIND-DC","url":"https://clinicaltrials.gov/study/NCT02993315","created_at":"2021-01-18T14:43:33.201Z","updated_at":"2025-02-25T16:59:22.630Z","phase":"Phase 3","brief_title":"Melanoma Patients Immunized with Natural DenDritic Cells","source_id_and_acronym":"NCT02993315 - MIND-DC","lead_sponsor":"Radboud University Medical Center","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"],"overall_status":"Completed","enrollment":" Enrollment 148","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 01/01/2024","primary_completion_date":" 01/01/2024","study_txt":" Completion: 05/01/2024","study_completion_date":" 05/01/2024","last_update_posted":"2025-02-03"},{"id":"82a9f948-41ce-4550-9b50-cbb7d53e0d09","acronym":"MK-3475A-F11","url":"https://clinicaltrials.gov/study/NCT06099782","created_at":"2023-10-25T19:14:04.742Z","updated_at":"2025-02-25T17:32:30.275Z","phase":"Phase 2","brief_title":"A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)","source_id_and_acronym":"NCT06099782 - MK-3475A-F11","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" EGFR • ALK • ROS1","pipe":"","alterations":" ","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 144","initiation":"Initiation: 12/26/2023","start_date":" 12/26/2023","primary_txt":" Primary completion: 03/03/2025","primary_completion_date":" 03/03/2025","study_txt":" Completion: 11/16/2026","study_completion_date":" 11/16/2026","last_update_posted":"2025-01-31"},{"id":"5b5025e1-918a-44f3-b1e4-127e110ec295","acronym":"","url":"https://clinicaltrials.gov/study/NCT05026983","created_at":"2021-08-30T21:53:02.254Z","updated_at":"2025-02-25T17:30:53.797Z","phase":"Phase 2","brief_title":"Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases","source_id_and_acronym":"NCT05026983","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mektovi (binimetinib) • Braftovi (encorafenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 12/27/2021","start_date":" 12/27/2021","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2025-01-30"},{"id":"c140a8b8-ac68-4df9-988d-ebe6e54e87b6","acronym":"DETERMINE","url":"https://clinicaltrials.gov/study/NCT06194929","created_at":"2024-01-08T19:20:11.355Z","updated_at":"2025-02-25T17:32:44.459Z","phase":"Phase 1/2","brief_title":"Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma","source_id_and_acronym":"NCT06194929 - DETERMINE","lead_sponsor":"University of Utah","biomarkers":" NF1 • RAS","pipe":" | ","alterations":" BRAF V600E • BRAF V600K • BRAF wild-type • RAS mutation","tags":["NF1 • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600K • BRAF wild-type • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Braftovi (encorafenib) • Avmapki (avutometinib) • Fakzynja (defactinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 03/07/2024","start_date":" 03/07/2024","primary_txt":" Primary completion: 01/15/2028","primary_completion_date":" 01/15/2028","study_txt":" Completion: 01/15/2030","study_completion_date":" 01/15/2030","last_update_posted":"2025-01-30"},{"id":"d2fe552c-f100-425e-934e-b8a426721a46","acronym":"IGNYTE","url":"https://clinicaltrials.gov/study/NCT03767348","created_at":"2021-01-18T18:38:28.476Z","updated_at":"2025-02-25T14:27:51.295Z","phase":"Phase 2","brief_title":"Study of RP1 Monotherapy and RP1 in Combination With Nivolumab","source_id_and_acronym":"NCT03767348 - IGNYTE","lead_sponsor":"Replimune Inc.","biomarkers":" BRAF • MSI","pipe":" | ","alterations":" MSI-H/dMMR • BRAF mutation","tags":["BRAF • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Tudriqev (vusolimogene oderparepvec-wtpg)"],"overall_status":"Recruiting","enrollment":" Enrollment 340","initiation":"Initiation: 09/20/2017","start_date":" 09/20/2017","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2025-01-24"}]